WO2010015144A1 - 普拉格雷硫酸氢盐及其药物组合物和应用 - Google Patents
普拉格雷硫酸氢盐及其药物组合物和应用 Download PDFInfo
- Publication number
- WO2010015144A1 WO2010015144A1 PCT/CN2009/000860 CN2009000860W WO2010015144A1 WO 2010015144 A1 WO2010015144 A1 WO 2010015144A1 CN 2009000860 W CN2009000860 W CN 2009000860W WO 2010015144 A1 WO2010015144 A1 WO 2010015144A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prasugrel
- hydrogensulfate
- solvent
- sulfuric acid
- concentrated sulfuric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/056,324 US20110124675A1 (en) | 2007-12-11 | 2008-07-31 | The hydrosulfate of prasugrel, its pharmaceutical combination and use thereof |
JP2011520304A JP2011529859A (ja) | 2008-08-02 | 2009-07-31 | プラスグレル重硫酸塩及びその薬物組成物並びにその応用 |
KR1020117005005A KR20110045034A (ko) | 2008-08-02 | 2009-07-31 | 프라수그렐 황산수소염 및 이의 약제학적 조성물 및 용도 |
CN2009801281387A CN102099361B (zh) | 2007-12-11 | 2009-07-31 | 普拉格雷硫酸氢盐及其药物组合物和应用 |
EP09804444A EP2325187A4 (en) | 2008-08-02 | 2009-07-31 | PRASUGREL HYDROGENOSULFATE, ITS MEDICINAL COMPOUND AND USE THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101461014A CN101456864B (zh) | 2007-12-11 | 2008-08-02 | 普拉格雷硫酸盐、组合物及其制备方法 |
CN200810146101.4 | 2008-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010015144A1 true WO2010015144A1 (zh) | 2010-02-11 |
Family
ID=41664452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/000860 WO2010015144A1 (zh) | 2007-12-11 | 2009-07-31 | 普拉格雷硫酸氢盐及其药物组合物和应用 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2325187A4 (zh) |
JP (1) | JP2011529859A (zh) |
KR (1) | KR20110045034A (zh) |
WO (1) | WO2010015144A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011127300A1 (en) | 2010-04-08 | 2011-10-13 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of prasugrel salts |
US20130045251A1 (en) * | 2010-04-27 | 2013-02-21 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd | Pharmaceutical composition for improving solubility of prasugrel and its preparation method |
JP2013526488A (ja) * | 2010-05-13 | 2013-06-24 | ティエンジン インスティテュート オブ ファーマシューティカル リサーチ | シアノ基を含有するチエノピリジンエステル誘導体、その調製方法、使用および組成物 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160033792A (ko) | 2007-04-27 | 2016-03-28 | 사이덱스 파마슈티칼스, 인크. | 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법 |
US8236782B2 (en) | 2009-05-13 | 2012-08-07 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
HU231079B1 (hu) | 2016-06-23 | 2020-06-29 | Richter Gedeon Nyrt. | Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0542411A2 (en) | 1991-09-09 | 1993-05-19 | Sankyo Company Limited | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
CN1214031A (zh) | 1996-09-19 | 1999-04-14 | 大光炉材株式会社 | 用于生产致密浇注耐火材料的可浇注耐火材料组合物及其湿式喷射法 |
EP1298132A1 (en) | 2000-07-06 | 2003-04-02 | Sankyo Company, Limited | Hydropyridine derivative acid addition salts |
US20040024013A1 (en) | 2000-12-25 | 2004-02-05 | Sankyo Company, Limited | Medicinal compositions containing aspirin |
CN101177430A (zh) * | 2007-12-11 | 2008-05-14 | 鲁南制药集团股份有限公司 | 氢化吡啶衍生物及其盐的制备方法 |
WO2008060934A2 (en) * | 2006-11-14 | 2008-05-22 | Acusphere, Inc. | Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101456864B (zh) * | 2007-12-11 | 2011-04-13 | 鲁南制药集团股份有限公司 | 普拉格雷硫酸盐、组合物及其制备方法 |
DE602008002820D1 (de) * | 2008-04-25 | 2010-11-11 | Sandoz Ag | Hydrogensulfat von 2-Acetoxy-5-(a-cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7-tetrahydrothienoÄ3,2-cÜpyridin und dessen Zubereitung |
-
2009
- 2009-07-31 JP JP2011520304A patent/JP2011529859A/ja not_active Withdrawn
- 2009-07-31 WO PCT/CN2009/000860 patent/WO2010015144A1/zh active Application Filing
- 2009-07-31 EP EP09804444A patent/EP2325187A4/en not_active Withdrawn
- 2009-07-31 KR KR1020117005005A patent/KR20110045034A/ko not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0542411A2 (en) | 1991-09-09 | 1993-05-19 | Sankyo Company Limited | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
CN1214031A (zh) | 1996-09-19 | 1999-04-14 | 大光炉材株式会社 | 用于生产致密浇注耐火材料的可浇注耐火材料组合物及其湿式喷射法 |
EP1298132A1 (en) | 2000-07-06 | 2003-04-02 | Sankyo Company, Limited | Hydropyridine derivative acid addition salts |
US20040024013A1 (en) | 2000-12-25 | 2004-02-05 | Sankyo Company, Limited | Medicinal compositions containing aspirin |
WO2008060934A2 (en) * | 2006-11-14 | 2008-05-22 | Acusphere, Inc. | Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration |
CN101177430A (zh) * | 2007-12-11 | 2008-05-14 | 鲁南制药集团股份有限公司 | 氢化吡啶衍生物及其盐的制备方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2325187A4 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011127300A1 (en) | 2010-04-08 | 2011-10-13 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of prasugrel salts |
US8802854B2 (en) | 2010-04-08 | 2014-08-12 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of Prasugrel salts |
US9012641B2 (en) | 2010-04-08 | 2015-04-21 | Teva Pharmaceuticals Industries Ltd. | Crystalline forms of Prasugrel salts |
EP2883877A1 (en) | 2010-04-08 | 2015-06-17 | Teva Pharmaceutical Industries, Ltd. | Crystalline forms of prasugrel salts |
US20130045251A1 (en) * | 2010-04-27 | 2013-02-21 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd | Pharmaceutical composition for improving solubility of prasugrel and its preparation method |
JP2013525386A (ja) * | 2010-04-27 | 2013-06-20 | スン ユエン | プラスグレルの溶出速度を改善する医薬組成物及びその製造方法 |
US9050328B2 (en) * | 2010-04-27 | 2015-06-09 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Pharmaceutical composition for improving dissolution rate of prasugrel and its preparation method |
JP2013526488A (ja) * | 2010-05-13 | 2013-06-24 | ティエンジン インスティテュート オブ ファーマシューティカル リサーチ | シアノ基を含有するチエノピリジンエステル誘導体、その調製方法、使用および組成物 |
KR101453181B1 (ko) * | 2010-05-13 | 2014-10-22 | 톈진 인스티튜트 오브 파마슈티컬 리서치 | 시아노기를 함유하는 티에노피리딘 에스테르 유도체, 이들의 제조방법, 용도 및 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR20110045034A (ko) | 2011-05-03 |
JP2011529859A (ja) | 2011-12-15 |
EP2325187A1 (en) | 2011-05-25 |
EP2325187A4 (en) | 2011-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110124675A1 (en) | The hydrosulfate of prasugrel, its pharmaceutical combination and use thereof | |
TWI290927B (en) | 2-Acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine acid-additive salts | |
WO2010015144A1 (zh) | 普拉格雷硫酸氢盐及其药物组合物和应用 | |
US20090247532A1 (en) | Crystalline polymorph of sitagliptin phosphate and its preparation | |
JP2002518399A (ja) | 多形クロピドグレル硫酸水素塩フォーム | |
CN110054624B (zh) | 盐酸小檗碱与咖啡酸共晶物及制备方法和其组合物与用途 | |
JP5575979B2 (ja) | シアノ基を含有するチエノピリジンエステル誘導体、その調製方法、使用および組成物 | |
CA2536052A1 (en) | Novel crystalline compounds | |
JP2003246735A (ja) | ヒドロピリジン誘導体酸付加塩を含有する医薬 | |
WO2018072742A1 (zh) | 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法 | |
AU2003206755B2 (en) | Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds | |
WO2018165979A1 (zh) | 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的晶型及其制备方法和药物组合物 | |
JP2959598B2 (ja) | 光学活性なチエノトリアゾロジアゼピン化合物 | |
EP1542965A1 (en) | Bicalutamide forms | |
JP7266676B2 (ja) | チエノピリドン誘導体のカリウム塩一水和物及びその調製方法 | |
JP2007501274A (ja) | カベルゴリンの多形体 | |
KR102515847B1 (ko) | 융합된 트리사이클릭 감마-아미노산 유도체의 조성물 및 이의 제조 방법 | |
WO2019200502A1 (zh) | 玻玛西尼甲磺酸盐晶型及其制备方法和药物组合物 | |
KR20110097816A (ko) | 신규 화합물 | |
JP2020533401A (ja) | 不飽和脂肪族オレフィン性結合を含有するチエノピリジン誘導体、その調製方法および使用 | |
EP0573548B1 (en) | Neuroprotectant agents | |
KR102663976B1 (ko) | 티에노피리돈 유도체의 1수화물 칼륨염 및 이의 제조 방법 | |
WO2020225783A1 (ko) | Pi3k 저해제의 결정다형 및 이의 제조방법 | |
WO2013010502A1 (zh) | 一种普拉格雷的酸加成盐及其制备方法和用途 | |
JPH11512409A (ja) | 抗腫瘍剤・2−[2−[2−(ヒドロキシエチル)アミノ]エチル]−5−[[2−メチルアミノ)−エチル]アミノ]インダゾロ[4,3−gh]イソキノリン−6(2H)−オン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980128138.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09804444 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 13056324 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2011520304 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1307/CHENP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009804444 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117005005 Country of ref document: KR Kind code of ref document: A |